NO20020259D0 - Antisense-terapi for hormonregulerte tumorer - Google Patents

Antisense-terapi for hormonregulerte tumorer

Info

Publication number
NO20020259D0
NO20020259D0 NO20020259A NO20020259A NO20020259D0 NO 20020259 D0 NO20020259 D0 NO 20020259D0 NO 20020259 A NO20020259 A NO 20020259A NO 20020259 A NO20020259 A NO 20020259A NO 20020259 D0 NO20020259 D0 NO 20020259D0
Authority
NO
Norway
Prior art keywords
tumors
seq
odn
igfbp
mammals
Prior art date
Application number
NO20020259A
Other languages
English (en)
Other versions
NO332388B1 (no
NO20020259L (no
Inventor
Martin Gleave
Hideaki Miyake
Original Assignee
Univ British Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia filed Critical Univ British Columbia
Publication of NO20020259D0 publication Critical patent/NO20020259D0/no
Publication of NO20020259L publication Critical patent/NO20020259L/no
Publication of NO332388B1 publication Critical patent/NO332388B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20020259A 1999-07-19 2002-01-17 Sammensetning som omfatter antisense-oligonukleotider og anvendelse derav NO332388B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14449599P 1999-07-19 1999-07-19
PCT/CA2000/000853 WO2001005435A2 (en) 1999-07-19 2000-07-19 Antisense therapy for hormone-regulated tumors

Publications (3)

Publication Number Publication Date
NO20020259D0 true NO20020259D0 (no) 2002-01-17
NO20020259L NO20020259L (no) 2002-01-17
NO332388B1 NO332388B1 (no) 2012-09-10

Family

ID=22508861

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20020259A NO332388B1 (no) 1999-07-19 2002-01-17 Sammensetning som omfatter antisense-oligonukleotider og anvendelse derav

Country Status (13)

Country Link
US (1) US7297684B1 (no)
EP (1) EP1200579B1 (no)
JP (1) JP5121106B2 (no)
KR (2) KR100779752B1 (no)
AT (1) ATE393220T1 (no)
AU (1) AU772480B2 (no)
CA (1) CA2375467C (no)
DE (1) DE60038680T2 (no)
HU (1) HU228465B1 (no)
IL (2) IL146565A0 (no)
NO (1) NO332388B1 (no)
NZ (1) NZ516701A (no)
WO (1) WO2001005435A2 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR633101A0 (en) * 2001-07-13 2001-08-02 University Of Sydney, The Method
NZ577565A (en) * 2001-10-09 2010-10-29 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
US6750019B2 (en) * 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
AU2003237616B2 (en) 2002-01-17 2007-07-05 The University Of British Columbia Bispecific antisense oligonucleotides that inhibit IGFBP-2 and IGFBP-5 and methods of using same
KR101117673B1 (ko) 2002-08-21 2012-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 암-관련 단백질을 표적으로 하는 알엔에이아이 프로브
ES2345330T3 (es) 2002-10-02 2010-09-21 The University Of British Columbia Oligonucleotidos para el tratamiento del cancer de prostata y otros canceres.
US8722872B2 (en) 2002-10-02 2014-05-13 The University Of British Columbia Compositions and methods for treatment of prostate and other cancers
WO2005030260A1 (en) * 2003-10-01 2005-04-07 The University Of British Columbia Bispecific oligonucleotide for the treatment of cns malignancies
PT2444505T (pt) * 2004-07-23 2017-01-13 Pacific Edge Ltd Marcadores urinários para a deteção de cancro da bexiga
WO2008106781A1 (en) 2007-03-05 2008-09-12 The University Of British Columbia Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
JP5390179B2 (ja) * 2008-12-24 2014-01-15 花王株式会社 Ｉｇｆｂｐ−５発現抑制剤
WO2010146059A2 (en) 2009-06-16 2010-12-23 F. Hoffmann-La Roche Ag Biomarkers for igf-1r inhibitor therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2090702A1 (en) 1990-08-28 1992-03-01 Michael C. Kiefer Insulin-like growth factor binding protein igfbp-5
JPH06503947A (ja) 1990-08-28 1994-05-12 カイロン　コーポレイション Ｉｇｆｂｐ―５をコードする遺伝物質
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression

Also Published As

Publication number Publication date
HUP0201868A2 (en) 2002-12-28
DE60038680D1 (de) 2008-06-05
DE60038680T2 (de) 2009-05-07
KR100856475B1 (ko) 2008-09-08
NZ516701A (en) 2004-11-26
KR20070036180A (ko) 2007-04-02
US7297684B1 (en) 2007-11-20
JP5121106B2 (ja) 2013-01-16
NO332388B1 (no) 2012-09-10
WO2001005435A2 (en) 2001-01-25
KR100779752B1 (ko) 2007-11-27
CA2375467C (en) 2013-10-29
IL146565A0 (en) 2002-07-25
HU228465B1 (en) 2013-03-28
ATE393220T1 (de) 2008-05-15
EP1200579B1 (en) 2008-04-23
AU6144500A (en) 2001-02-05
IL146565A (en) 2012-02-29
WO2001005435A3 (en) 2001-03-22
CA2375467A1 (en) 2001-01-25
KR20020033735A (ko) 2002-05-07
EP1200579A2 (en) 2002-05-02
JP2003504418A (ja) 2003-02-04
NO20020259L (no) 2002-01-17
AU772480B2 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
NO20020259L (no) Antisense-terapi for hormonregulerte tumorer
CA2046916A1 (en) Methods and compositions for treatment of cancer using oligonucleotides
EP0702563A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER AND HYPERPROLIFERATIVE DISEASES
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
DK0928335T3 (da) Fremgangsmåde til anvendelse af oligonukleotider med modificerede CpG-dinukleosider
NO20014058L (no) TRPM-2-antisense-terapi
RO93650B (ro) Procedeu pentru obtinerea unei polipeptide umane fiziologic activa
AU2001287639A1 (en) Trp8, trp9 and trp10, markers for cancer
AU688101B2 (en) Live vaccine for the treatment of tumour diseases
ATE287958T1 (de) Verbesserte krebstherapie
DE60144525D1 (de) Des protein (igfbp)-2-oligodeoxynukleotide zur behandlung von prostatakrebs
HUT64569A (en) A process for preparing polypeptide-type compounds usefules for medical treatment of the human body
EP1070122A4 (en) INDUCTION OF THE EXPRESSION OF APOPTOTIC OR CYTOTOXIC GENES BY CO-SUPPORT OF ADENOVIRAL MEDIATED GENES
HUP0104046A2 (hu) Adenovírus-közvetített génterápia
YU77002A (sh) Postupak i preparat za tretiranje kancera putem davanja hemoterapeutskog agensa koji indukuje apoptozis
AU6349400A (en) Methods for treatment of hyperproliferative diseases using human mda-7
US20100247623A1 (en) Cancer Stem Cell Vaccine
CN117431241B (zh) 靶向LMP1的shRNA、载体及其应用
ATE552887T1 (de) Tumorspezifischer vektor für die gentherapie
WO2001087039A3 (en) Treatment of neoplasia / transformation using pituitary tumor transforming gene 2
WO2000020589A3 (en) PTANs: TESTIS SPECIFIC PROTEINS EXPRESSED IN PROSTATE CANCER
NZ502270A (en) Derivatives of mammalian secretory peptide-9 for treating cancer and may be used in conjunction with cytokines
DE69938501D1 (de) Verwendung von prohibitin-rns in krebsbehandlung
AU4935600A (en) New vaccine formulations - 2
Sikora et al. Genetic drug activation strategies for breast cancer

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees